| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Current Ratio | 7.69 | 10.55 | 9.75 | 20.27 | 34.46 | — |
| Quick Ratio | 7.69 | 10.55 | 9.75 | 20.27 | 34.46 | — |
| Debt / Equity | 0.01 | 0.01 | 0.03 | 0.02 | -0.21 | 0.00 |
| ROE | -69.24% | -45.57% | -49.83% | -18.28% | 68.22% | 63.07% |
| ROA | -60.06% | -40.98% | -43.68% | -17.20% | -15.24% | -242.84% |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book Value / Share | 2.92 | 5.23 | 5.49 | 41.36 | -13.66 | -0.65 |
Acrivon Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology medicines tailored for patients whose tumors are predicted to be sensitive to specific treatments through its proprietary generative phosphoproteomics platform. The company operates the Acrivon Predictive Precision Proteomics (AP3) platform, which generates drug-specific proprietary OncoSignature companion diagnostics to precisely identify suitable patients for its drug candidates, enabling a precision medicine approach in cancer therapy. Its lead clinical candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, advancing in a registrational-intent Phase 2 study for endometrial cancer and showing activity in platinum-resistant ovarian cancer and squamous cell carcinomas such as head and neck and anal cancers. Additionally, ACR-2316, a novel WEE1/PKMYT1 inhibitor designed using AP3 for enhanced single-agent potency, is in Phase 1 clinical trials. Headquartered in Watertown, Massachusetts, Acrivon Therapeutics Inc. plays a key role in advancing targeted oncology therapies by integrating proteomics-driven patient selection with innovative drug discovery to address unmet needs in precision cancer care.